Other languages MediciNova, Inc.

Equities

MNOV

US58468P2065

Real-time Estimate Cboe BZX Other stock markets 03:21:50 2024-06-13 pm EDT			5-day change	1st Jan Change
1.365 ^USD	+1.11%		-0.72%	-8.00%

Jun. 05	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Various Solid Cancer	CI
Jun. 03	MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 in Glioblastoma Patients At the American Society of Clinical Oncology Annual Meeting 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Various Solid Cancer	Jun. 05
MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 in Glioblastoma Patients At the American Society of Clinical Oncology Annual Meeting 2024	Jun. 03
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Eye Cancer	May. 20
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	May. 14
MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166	May. 07
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	Mar. 26
Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology	Mar. 12
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 for the Treatment of Macular Injury in China	Jan. 17
Top Premarket Gainers	Jan. 12
MediciNova, Inc. Announces Abstract Regarding MN-166 in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	Dec. 21
MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 for the Treatment of Progressive MS in Europe	Dec. 06
Sector Update: Health Care Stocks Lean Down Premarket Monday	Nov. 20
MediciNova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
MediciNova Secures Patent Notice of Allowance in Canada for Amyotrophic Lateral Sclerosis Combination Treatment	23-10-11
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis in Canada	23-10-10
MediciNova Says it Received $1 Million Clinical Development Milestone Payment Under Deal With Sanofi Subsidiary	23-10-05
Sector Update: Health Care Stocks Gain Premarket Thursday	23-09-28
MediciNova Says Ibudilast Improved Pulmonary Function in Lung Injury Study	23-09-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages MediciNova, Inc.

Equities

MNOV

US58468P2065

Other languages

Filters